Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits by Teumer, A. (Alexander) et al.
Genomewide meta-analysis identifies loci associated with IGF-I
and IGFBP-3 levels with impact on age-related traits
Alexander Teumer,1,2,* Qibin Qi,3,* Maria Nethander,4
Hugues Aschard,5 Stefania Bandinelli,6 Marian Beekman,7
Sonja I. Berndt,8 Martin Bidlingmaier,9 Linda Broer,10,11
CHARGE Longevity Working Group, Anne Cappola,12 Gian
Paolo Ceda,13,14 Stephen Chanock,2 Ming-Huei Chen,15,16
Tai C. Chen,17 Yii-Der Ida Chen,18 Jonathan Chung,19
Fabiola Del Greco Miglianico,20,21 Joel Eriksson,22 Luigi
Ferrucci,23 Nele Friedrich,24 Carsten Gnewuch,25 Mark O.
Goodarzi,26 Niels Grarup,27 Tingwei Guo,19 Elke Hammer,2
Richard B. Hayes,28 Andrew A. Hicks,20 Albert Hofman,29
Jeanine J. Houwing-Duistermaat,30 Frank Hu,31,32 David J.
Hunter,31,33 Lise L. Husemoen,34 Aaron Isaacs,35,36 Kevin B.
Jacobs,2 Joop A. M. J. L. Janssen,37 John-Olov Jansson,38
Nico Jehmlich,2,39 Simon Johnson,19 Anders Juul,40 Magnus
Karlsson,41 Tuomas O. Kilpelainen,27 Peter Kovacs,42 Peter
Kraft,32,33,43 Chao Li,19 Allan Linneberg,34,44,45 Yongmei
Liu,46 Ruth J. F. Loos,47 Body Composition Genetics
Consortium, Mattias Lorentzon,22 Yingchang Lu,47 Marcello
Maggio,13,14 Reedik Magi,48,49 James Meigs,50,51 Dan
Mellstr€om,22 Matthias Nauck,31,33 Anne B. Newman,52
Michael N. Pollak,53 Peter P. Pramstaller,20,21 Inga
Prokopenko,54 Bruce M. Psaty,55 Martin Reincke,9 Eric B.
Rimm,31,32 Jerome I. Rotter,18 Aude Saint Pierre,56 Claudia
Schurmann,57,58 Sudha Seshadri,15,16 Klara Sj€ogren,22 P.
Eline Slagboom,7 Howard D. Strickler,3 Michael Stumvoll,42
Yousin Suh,19,59,60 Qi Sun,31,32 Cuilin Zhang,61 Johan
Svensson,22 Toshiko Tanaka,23 Archana Tare,19 Anke
T€onjes,62 Hae-Won Uh,30 Cornelia M. van Duijn,35,36 Diana
van Heemst,63 Liesbeth Vandenput,22 Ramachandran S.
Vasan,64,65 Uwe V€olker,2 Sara M. Willems,35 Claes
Ohlsson,22 Henri Wallaschofski24 and Robert C. Kaplan3
1Institute for Community Medicine, University Medicine Greifswald, 17475,
Greifswald, Germany
2Interfaculty Institute for Genetics and Functional Genomics, University
Medicine Greifswald, 17475, Greifswald, Germany
3Department of Epidemiology and Population Health, Albert Einstein College
of Medicine, Bronx, NY 10461, USA
4Bioinformatics Core Facility, The Sahlgrenska Academy, University of
Gothenburg, Gothenburg 40530, Sweden
5Program in Genetic Epidemiology and Statistical Genetics, Department of
Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
6Geriatric Unit, Azienda Sanitaria di Firenze (ASF), Florence, Italy
7Molecular Epidemiology, Leiden University Medical Center, Leiden 2300 RC,
The Netherlands
8Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD 20892, USA
9Medizinische Klinik und Poliklinik IV, Klinikum der Universitaet Muenchen,
80336, Munich, Germany
10Department of Epidemiology, Subdivision Genetic Epidemiology, Erasmus
Medical Center, Postbus 2040, 3000 CA, Rotterdam, The Netherlands
11Department of Internal Medicine, Erasmus Medical Center, Postbus
2040,3000 CA, Rotterdam, The Netherlands
12Division of Endocrinology, Diabetes, and Metabolism,Department of
Medicine, Center for Clinical Epidemiology and Biostatistics, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
13Section of Geriatrics, Department of Clinical and Experimental Medicine,
University of Parma, Parma, Italy
14Geriatric Rehabilitation Department, University-Hospital of Parma, Parma,
Italy
15Framingham Heart Study, Framingham, MA 01702, USA
16Department of Neurology, Boston University School of Medicine, Boston,
MA 02118, USA
17Section of Endocrinology, Diabetes & Nutrition,Boston University School of
Medicine, Boston, MA 02118, USA
18Institute for Translational Genomics and Population Sciences, Los Angeles
BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
90502, USA
19Department of Genetics, Albert Einstein College of Medicine, Bronx, NY
10461, USA
20Center for Biomedicine, European Academy Bozen/Bolzano (EURAC),
Bolzano 39100, Italy
21Affiliated Institute of the University of L€ubeck, 23562, L€ubeck, Germany
22Department of Internal Medicine and Clinical Nutrition, Institute of
Medicine, Sahlgrenska Academy, University of Gothenburg, 41345,
Gothenburg, Sweden
23Translational Gerontology Branch, National Institute on Aging, Baltimore,
MD 21225, USA
24Institute of Clinical Chemistry and Laboratory Medicine, University
Medicine Greifswald, 17475, Greifswald, Germany
25Institute for Clinical Chemistry and Laboratory Medicine, Regensburg
University Medical Center, D-93053, Regensburg, Germany
26Division of Endocrinology, Diabetes and Metabolism, Department of
Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
27The Novo Nordisk Foundation Center for Basic Metabolic Research,
Section of Metabolic Genetics, Faculty of Health and Medical Sciences,
University of Copenhagen, 2100, Copenhagen, Denmark
28Division of Epidemiology, Department of Population Health, New York
University School of Medicine, New York, NY 10016, USA
29Department of Epidemiology, Erasmus University Medical Center,
Rotterdam 3000 CA, The Netherlands
30Leiden University Medical Center, Medical Statistics and Bioinformatics,
Leiden 2300 RC, The Netherlands
31Department of Nutrition, Harvard School of Public Health, Boston, MA
02115, USA
32Channing Division of Network Medicine, Department of Medicine, Brigham
and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
33Department of Epidemiology and Statistical Genetics, Harvard School of
Public Health, Boston, MA 02115, USA
34Research Centre for Prevention and Health, Capital Region of Denmark,
Copenhagen DK-2600, Denmark
35Genetic Epidemiology Unit, Department of Epidemiology, Erasmus
University Medical Center, Rotterdam 3000 CA, The Netherland
36Centre for Medical Systems Biology, Leiden 2300 RC, The Netherlands
37Department of Internal Medicine, Erasmus University Medical Center,
Rotterdam 3000 CA, The Netherlands
38Department of Physiology, Institute of Neuroscience and Physiology,
Sahlgrenska Academy, University of Gothenburg, 41345, Gothenburg,
Sweden
Correspondence
Robert C. Kaplan, 1300 Morris Park Avenue, Albert Einstein College of Medicine,
Bronx, NY 10461, USA. Tel.: 718 430 4076; fax: x718-430-3588;
e-mail: robert.kaplan@einstein.yu.edu
*These authors contributed equally to this work.
Accepted for publication 1 April 2016
ª 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
811
Aging Cell (2016) 15, pp811–824 Doi: 10.1111/acel.12490
Ag
in
g 
Ce
ll
39Department of Proteomics, Helmholtz – Centre for Environmental Research
– UFZ, 04318, Leipzig, Germany
40Department of Growth and Reproduction, Rigshospitalet, University of
Copenhagen, Copenhagen DK-2100, Denmark
41Clinical and Molecular Osteoporosis Research Unit, Department of Clinical
Sciences, Lund University, 20502, Malm€o, Sweden
42IFB Adiposity Diseases, University of Leipzig, 04103, Leipzig, Germany
43Department of Biostatistics, Harvard School of Public Health, Boston, MA
02115, USA
44Department of Clinical Experimental Research, Glostrup University Hospital,
Copenhagen DK-2600, Denmark
45Department of Clinical Medicine, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen DK-2200, Denmark
46Division of Public Health Sciences, Department of Epidemiology and
Prevention, Wake Forest School of Medicine, Winston-Salem, NC 27157,
USA
47The Genetics of Obesity and Related Metabolic Traits Program, The Charles
Bronfman Institute for Personalized Medicine, The Icahn School of Medicine
at Mount Sinai, New York, NY 10029, USA
48Estonian Genome Center, University of Tartu, Tartu, Estonia
49Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford,
UK
50General Medicine Division, Department of Medicine, Massachusetts
General Hospital, Boston, MA 02114, USA
51Division of General Medicine, Harvard Medical School, Boston, MA 02115,
USA
52Department of Epidemiology, School of Public Health, University of
Pittsburgh, Pittsburgh, PA 15261, USA
53Departments of Experimental Medicine and Oncology, McGill University,
Montreal, Quebec Canada, H3A 0G4
54Department of Genomics of Common Disease, School of Public Health,
Imperial College London, London W12ONN, UK
55Departments of Epidemiology, Medicine and Health Services, University of
Washington, Seattle, WA 98101, USA
56INSERM U1078, Brest, France
57The Charles Bronfman Institute for Personalized Medicine, Icahn School of
Medicine at Mount Sinai, New York, NY 10029, USA
58The Genetics of Obesity and Related Metabolic Traits Program, Icahn
School of Medicine at Mount Sinai, New York, NY 10029, USA
59Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
10461, USA
60Institute of Aging Research, Guangdong Medical College, Dongguan,
China
61Epidemiology Branch, Division of Epidemiology, Statistics and Prevention
Research, Eunice Kennedy Shriver National Institute of Child Health and
Human Development, National Institutes of Health, 6100 Executive Blvd,
Rockville, MD 20852, USA
62Medical Department, University of Leipzig, 04103, Leipzig, Germany
63Gerontology and Geriatrics, Leiden University Medical Center, Leiden 2300
RC, The Netherlands
64Boston University and National Heart, Lung & Blood Institute’s Framingham
Heart Study, Framingham, MA 01702, USA
65Preventive Medicine & Epidemiology Section, Boston University School of
Medicine, Boston, MA 02118, USA
Summary
The growth hormone/insulin-like growth factor (IGF) axis can be
manipulated in animal models to promote longevity, and IGF-
related proteins including IGF-I and IGF-binding protein-3 (IGFBP-
3) have also been implicated in risk of human diseases including
cardiovascular diseases, diabetes, and cancer. Through genome-
wide association study of up to 30 884 adults of European
ancestry from 21 studies, we confirmed and extended the list of
previously identified loci associated with circulating IGF-I and
IGFBP-3 concentrations (IGF1, IGFBP3, GCKR, TNS3, GHSR, FOXO3,
ASXL2, NUBP2/IGFALS, SORCS2, and CELSR2). Significant sex
interactions, which were characterized by different genotype–
phenotype associations between men and women, were found
only for associations of IGFBP-3 concentrations with SNPs at the
loci IGFBP3 and SORCS2. Analyses of SNPs, gene expression, and
protein levels suggested that interplay between IGFBP3 and
genes within the NUBP2 locus (IGFALS and HAGH) may affect
circulating IGF-I and IGFBP-3 concentrations. The IGF-I-decreasing
allele of SNP rs934073, which is an eQTL of ASXL2, was associated
with lower adiposity and higher likelihood of survival beyond
90 years. The known longevity-associated variant rs2153960
(FOXO3) was observed to be a genomewide significant SNP for
IGF-I concentrations. Bioinformatics analysis suggested enrich-
ment of putative regulatory elements among these IGF-I- and
IGFBP-3-associated loci, particularly of rs646776 at CELSR2. In
conclusion, this study identified several loci associated with
circulating IGF-I and IGFBP-3 concentrations and provides clues to
the potential role of the IGF axis in mediating effects of known
(FOXO3) and novel (ASXL2) longevity-associated loci.
Key words: aging; genomewide association study; growth
hormone axis; IGF-I; IGFBP-3; longevity.
Introduction
The insulin-like growth factor (IGF) axis is an evolutionarily conserved
system that plays important biologic roles in embryonic development,
growth, and adulthood (Le Roith, 1997). IGF-I mediates most of the
activity of growth hormone (GH). The GH/IGF system consists of two
ligands (IGF-I and IGF-II), six IGF-binding proteins (IGFBP-1-6), and three
IGF receptor subtypes (IGF-I receptor, IGF-II receptor, and insulin
receptor) (Jones & Clemmons, 1995). IGF-I promotes mitosis and cell
cycle progression and is involved in human postnatal growth and
development. Circulating IGF-I is mainly bound to IGF-binding proteins
(IGFBPs) (Fowlkes, 1997), which affect activity (Lee et al., 1997) and half-
life of IGF-I (Guler et al., 1989). From the clinical point of view, the
measurement of IGF-I and IGFBP-3 blood concentrations is an important
tool in establishing the diagnosis as well as monitoring treatment of GH-
related diseases (Ho & Participants, 2007; Cohen et al., 2008; Melmed
et al., 2009).
Circulating concentrations of IGF-I and IGFBP-3 have been associated
with risk of type 2 diabetes, cardiovascular diseases, cancer, and
mortality in epidemiological studies (Juul et al., 2002; Vasan et al., 2003;
Renehan et al., 2004; Kaplan et al., 2007; Friedrich et al., 2009; Burgers
et al., 2011; Rajpathak et al., 2012). In animal models, diminished IGF-I/
insulin signaling has been associated with extended lifespans (Ziv & Hu,
2011), although the role of the IGF axis in human longevity remains
inconclusive. Human genetic studies have suggested an association
between polymorphisms in IGF-I signaling pathway genes and longevity
(Willcox et al., 2008; Ziv & Hu, 2011; Di Bona et al., 2014). Heritability
studies have provided evidence for a substantial genetic contribution to
circulating concentrations of IGF-I (with heritability estimates ~40–60%)
and IGFBP-3 (80%) (Harrela et al., 1996; Hong et al., 1996; Souren
et al., 2007). Identifying genetic determinants of circulating IGF-I and
IGFBP-3 could lead to a better understanding of the biological basis of
these factors in relation to human health and might identify pathways or
susceptibility biomarkers that may assist with the development of
interventions that target IGF-I, its receptors, and binding proteins.
Our prior genomewide association study (GWAS) (N = 10 280)
identified four loci with genomewide significant (P < 5 9 108)
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associations with circulating IGF-I and IGFBP-3 concentrations, including
SNPs in or near IGFBP3, TNS3, SORCS2, and NUBP2/IGFALS, as well as
three additional loci with suggestive associations (P < 1 9 106) in or
near RPA3, SPOCK2, and FOXO3 (Kaplan et al., 2011). Some of these
genes are involved in well-described IGF regulatory or signaling
pathways (such as IGFBP3 and IGFALS) (Deal et al., 2001; Gu et al.,
2010; Schumacher et al., 2010) and are believed to influence traits that
are also associated with concentrations or bioactivity of IGFs (e.g.,
FOXO3 locus associated with longevity (Willcox et al., 2008) and IGFBP3
locus associated with hip osteoarthritis (Evans et al., 2014)). To identify
additional genetic variants with smaller effect sizes and enable sex
specific analyses, we expanded our GWAS meta-analysis to include up to
a total of 30 884 individuals of European ancestry from 21 studies with
measured circulating concentrations of IGF-I and IGFBP-3. In addition,
using published GWAS data, we also performed lookups of associations
of identified IGF-I and IGFBP-3 loci with survival beyond 90 years and
other age-related clinical traits.
Results
Characteristics of study samples
An overview of the study samples and data collection methods can be
found in Tables S1 and S2 (Supporting information). Analyses of IGF-I
included up to 30 884 individuals (14 424 men and 16 460 women)
from 21 studies and analyses of IGFBP-3 included up to 18 995
individuals (8053 men and 10 942 women) from 13 studies.
Loci associated with circulating IGF-I and IGFBP-3
concentrations
An overview of the GWAS meta-analysis results is given by the
Manhattan plots in Fig. 1 and in Fig. S1 (Supporting information). There
was no indication of inflated test statistics (i.e., due to unaccounted
population stratification) as seen by the quantile–quantile (QQ) plots, and
genomic control lambda ranged from 1.02 to 1.08 for the meta-analysis
results (Fig. S2, Supporting information) and from 0.98 to 1.08 (median
1.01) for the individual GWAS results. All lead SNPs (independent SNPs
with the smallest P-value within a locus, see Methods) had a good
imputation quality across the studies (median imputation quality >0.9).
After the final stage, which combines results of stages 1 and 2 plus de
novo genotyping in stage 3, we found seven genomewide significant loci
(P < 5.0 9 108) associated with circulating IGF-I concentration
(Table 1). In addition to the known locus near TNS3, we identified
new loci in or near GCKR, IGF1, FOXO3, ASXL2, NUBP2, and GHSR
associated with IGF-I concentrations.
We found genomewide significant associations with IGFBP-3 con-
centration for SNPs in or near IGFBP3, TNS3, NUBP2, and SORCS2, thus
confirming all four previously known loci (Table 1). The SNPs at TNS3
and NUBP2 were genomewide significantly associated with both IGF-I
and IGFBP-3 concentrations and had the same direction of effect for
each circulating protein.
For six of ten genomewide significant SNPs, effects were in the same
direction of association for IGF-I concentrations and IGFBP-3 concentra-
tions (Table 1).
Detailed results of the significant associations after the final stage can
be found in Table 1. Results of the individual analysis stages appear in
Table S3 (Supporting information). Regional association plots are shown
in Figs S3 and S4 (Supporting information).
Bivariate analysis of IGF-I and IGFBP-3
We performed a bivariate analysis of IGF-I and IGFBP-3. By leveraging
shared variance between the two outcomes, this analysis can have
improved power to identify SNPs associated with both IGF-I and
IGFBP-3 concentrations, especially in the case of SNPs that have
opposite effects on positively correlated traits (Aschard et al., 2014).
The bivariate analysis identified a new locus at CELSR2 (Table 1),
which had nominal association with IGFBP-3 (P = 2.08 9 1005) and
IGF-1 (P = 0.0096) in the univariate analysis. SNP rs646776 at CELSR2
had opposite effects on the two traits, being negatively associated
with IGF-1 and positively associated with IGFBP-3 (Table 1, Table S4
and Fig. S5, Supporting information). In addition, SNPs at IGFBP3,
TNS3, NUBP2, SORCS2, GCKR, IGF1, and FOXO3, identified in the
univariate analysis, also showed genomewide significant associations
in the bivariate analysis.
Interaction by sex
The sex-stratified analyses revealed no additional discoveries that were
not detected in the overall population. Although the direction of effect
was similar for IGFBP3 and SORCS2 SNPs within sex subgroups, these
two SNPs were found to have significantly different association effect
sizes between men and women for IGFBP-3, consistent with stronger
associations in women. These findings of sex interaction maintained
statistical significance after Bonferroni correction for the 12 tested
genomewide significant lead SNPs (P < 0.004) (Table S5, Supporting
information).
Gene-based analysis (VEGAS)
Gene-based analyses showed several significant IGF-I-associated genes
within or close to the GCKR GWAS locus: EIF2B4, FNDC4, GCKR, IFT172,
PPM1G, SNX17, ZNF513, GTF3C2, KRTCAP3, MPV17, and NRBP1
(associated with IGF-I). New gene-based associations that were not
covered by a single SNP GWAS association were found for C6orf173
(chromosome 6) on IGF-I concentration. The following genes of the
NUBP2 GWAS locus were associated with circulating IGFBP-3 concen-
tration: EME2, IGFALS, MAPK8IP3, MRPS34, NME3, NUBP2, HS3ST6,
RPL3L, SEPX1, and SPSB. Two genes, IGFBP1 and IGFBP3, at the IGFBP3
locus were associated IGFBP-3 concentration.
Lookup for expression quantitative trait loci associations
A lookup of the lead SNPs for cis expression quantitative trait loci (eQTL)
was performed in the publicly available database of whole blood eQTL
associations (Westra et al., 2013). For the following SNPs, one or more
cis eQTL associations were found: rs1065656 (NUBP2), rs11977526
(IGFBP3), rs2153960 (FOXO3), rs509035 (GHSR), rs780093 (GCKR),
rs934073 (ASXL2), and rs978458 (IGF1) (Table 2).
Additionally, using a similar strategy we performed lookup in the
MuTHER consortium (Grundberg et al., 2012) for cis eQTL associations
found in fat cell, skin cell, and lymphoblastic cell lines (LCL). After
Bonferroni correction for 297 lookups of three different traits
(P < 5.6 9 105), rs1065656 (NUBP2) showed significant associations,
specifically with FAHD1 (all tissues) and HAGH (fat cells and LCL)
(Table S6, Supporting information). Furthermore, both genes were also
significant in whole blood cis eQTL for the SNP rs1065656 (NUBP2)
(Table 2).
GWAS reveals IGF-I- and IGFBP-3-associated loci, A. Teumer et al. 813
ª 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
GWAS reveals IGF-I- and IGFBP-3-associated loci, A. Teumer et al.814
ª 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Associations of gene expression with circulating IGF-I and
IGFBP-3 concentrations
We next sought to link associations between SNPs and circulating IGF-I
and IGFBP-3 concentrations, with cis eQTL associations of the same
SNPs. In the 986 samples of the SHIP-TREND cohort, we examined
associations between whole blood mRNA expression levels of the genes
located in a 500-kb vicinity of our significant lead SNPs and circulating
IGF-I and IGFBP-3 concentrations. Significance of the 323 array probe
trait associations was defined by a false discovery rate (FDR) <0.05. Only
mRNA levels of genes in vicinity of the NUBP2 GWAS locus were
significantly associated with IGF-I concentration (gene SEPX1) or IGFBP-3
concentration (genes HAGH and RPS2). Of note, HAGH was the gene on
which the corresponding lead SNP (rs1065656) had also a significant cis
eQTL. The complete gene expression association results are listed in
Table S7 (Supporting information).
Table 1 Loci associated with IGF-I and IGFBP-3 concentrations in men and women combined samples at genomewide significance (P < 5 9 108) after final stage
Trait SNP A1 A2 F1 P I² Chr Position
Nearest
gene
Gene
distance
Direction effect
IGF-I IGFBP-3
IGF-I* rs700753 C G 0.35 1.60E-23 4.2 7 46,720,209 TNS3 561067 – –
IGF-I rs780093 T C 0.41 2.19E-13 24.5 2 27,596,107 GCKR 0 – +
IGF-I rs978458 T C 0.26 1.56E-10 0.0 12 101,326,369 IGF1 0 + –
IGF-I rs2153960 A G 0.69 5.16E-09 22.5 6 109,082,339 FOXO3 0 + +
IGF-I rs934073 C G 0.71 6.48E-09 21.8 2 25,790,669 ASXL2 25087 – –
IGF-I rs1065656 C G 0.31 1.17E-08 47.9 16 1,778,837 NUBP2 0 – –
IGF-I rs509035 A G 0.31 2.09E-08 0.0 3 173,646,143 GHSR 0 + +
IGFBP-3* rs11977526 A G 0.41 4.16E-161 51.5 7 45,974,635 IGFBP3 47239
IGFBP-3* rs700753 C G 0.35 1.11E-46 26.7 7 46,720,209 TNS3 561067 – +
IGFBP-3* rs1065656 C G 0.31 8.55E-23 24.1 16 1,778,837 NUBP2 0 – –
IGFBP-3* rs4234798 T G 0.39 8.86E-19 0.0 4 7,270,834 SORCS2 0 – –
Bivariate analysis rs646776 T C 0.78 6.87E-9 26.1/43.1 1 109,620,053 CELSR2 152 – –
‘’ = coding allele associated with lower IGF-1 and IGFBP-3 levels (indicated by bold italicized text were genomewide significant); ‘+’ = coding allele associated with higher
IGF-1 and IGFBP-3 levels (indicated by bold italicized text were genomewide significant); Chr = chromosome; A1 = coding allele; A2 = other allele; F1 = frequency of
coding allele.
*Known association.
Table 2 Results of significant whole blood eQTL associations of the genomewide significant lead SNPs
SNP
GWAS
locus
eQTL
p-value Chr
Probe center
position Probe name
SNP
alleles
Effect
allele
Effect
direction EQTL gene
rs1065656 NUBP2 3.66E-04 16 1,829,861 1710332 C/G C + FAHD1
rs1065656 NUBP2 4.28E-12 16 1,799,259 4900333 C/G C  HAGH
rs1065656 NUBP2 3.78E-04 16 1,809,162 1780356 C/G C  HAGH
rs1065656 NUBP2 9.35E-04 16 1,760,172 5270575 C/G C + MAPK8IP3
rs1065656 NUBP2 3.34E-05 16 1,762,997 6110307 C/G C + MRPS34
rs1065656 NUBP2 7.75E-34 16 1,760,510 6450424 C/G C + NME3
rs1065656 NUBP2 1.09E-14 16 1,778,738 6960730 C/G C  NUBP2
rs1065656 NUBP2 9.87E-05 16 1,766,816 2850433 C/G C  SPSB3
rs2153960 FOXO3 2.95E-06 6 109,129,272 7200189 G/A G  HS.133419
rs509035 GHSR 5.97E-05 3 173,706,575 870202 G/A A + TNFSF10
rs780093 GCKR 2.46E-04 2 27,440,911 5960546 T/C T  EIF2B4
rs780093 GCKR 5.70E-04 2 27,440,904 6370494 T/C T  EIF2B4
rs780093 GCKR 2.69E-05 2 27,518,384 430239 T/C T + NRBP1
rs780093 GCKR 1.00E-10 2 27,453,289 3360468 T/C T + SNX17
rs934073 ASXL2 5.96E-04 2 25,816,038 650075 G/C G + ASXL2
rs978458 IGF1 1.71E-03 12 101,115,257 990136 T/C T + C12ORF48
rs11977526 IGFBP3 1.84E-05 7 45,918,692 6840372 G/A A  IGFBP3
Chr, chromosome; eQTL, expression quantitative trait loci; GWSD, genomewide association study.
mRNA of probe and gene names marked in bold showed also significant association with circulating IGFBP-3 levels (P < 3.5 9 104).
Fig. 1 Manhattan plots of the combined stage 1 and 2 meta-analysis results of IGF-I and IGFBP-3 traits in the men and women combined sample. SNPs are plotted on the
x-axis according to their position on each chromosome with the -log10 association P-value on the y-axis. The upper solid horizontal line indicates the threshold for
genomewide significance. Known hits are colored in orange and new findings in blue. Plots are truncated on the y-axis to 20.
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Association with plasma protein levels
In 197 samples of the SHIP-TREND cohort, peptides of the following
proteins that were encoded by genes in a 500-kb vicinity of the lead
SNPs were examined for protein quantitative trait analyses (pQTL):
insulin-like growth factor-binding protein complex acid labile subunit
(ALS encoded by IGFALS at the NUBP2 locus), 28S ribosomal protein
S34, mitochondrial (RT34 encoded by MRPS34 at the NUBP2 locus),
insulin-like growth factor-binding protein 3 (IBP3 encoded by IGFBP3 at
the IGFBP3 locus), and coiled-coil domain-containing protein 121
(CC121 encoded by CCDC121 at the GCKR locus). Of the 32 tested
SNP peptide pairs, peptides of the ALS protein had significant pQTL at
FDR <0.05 (Table S8, Supporting information). Furthermore, strong
associations were found in the same samples for the pQTL-associated
peptides of ALS and IBP3 with circulating levels of IGF-I and IGFBP-3
(P < 1.0 9 106).
Allelic heterogeneity of the NUBP2 locus
To further examine the NUBP2 locus, we performed a conditional
analysis of this locus based on the meta-analysis results adjusting for the
lead SNP rs1065656. The analyses revealed an independent genome-
wide significant association of a second SNP rs11644716 with IGFBP-3
(P = 6.3 9 1014) and an opposite effect direction of the minor allele C
(MAF = 0.05) compared with the lead SNP rs1065656 (MAF = 0.31)
(r² = 0.03 between these two SNPs based on the HapMap R22
reference data). Although not genomewide significant, rs11644716
was also associated with circulating IGF-I concentration
(P = 1.8 9 106) and has an eQTL for HAGH (probe 4900333:
P = 3.2 9 105; probe 1780356: P = 0.003) and a pQTL with ALS
(eight peptides with P-value <0.01). In all cases, the effect directions
based on the minor allele of rs11644716 were opposite of that for the
minor allele of rs1065656.
Figure 2 summarizes the relationship between the lead SNPs at the
NUBP2 locus and gene expression levels, protein levels, and circulating
IGF-I and IGFBP-3 concentrations.
Associations with serum metabolites
Lead SNPs associated with IGF-I and IGFBP-3 concentrations were
examined in a published metabolite-SNP association database (Suhre
et al., 2011; Shin et al., 2014). The IGF-I-associated SNP rs780093 at
GCKR locus was associated with glucose/mannose ratio (P = 9.4 9
10143), and the IGFBP-3-associated SNP rs4234798 at SORCS2 locus
was associated with caprylate (8:0)/phenylalanine ratio
(P = 7.3 9 107).
Associations of top loci with age-related traits
We also examined the associations of the IGF-I- and IGFBP-3-associated
SNPs with anthropometric traits (height, BMI, waist-to-hip ratio, and fat
percentage) (Heid et al., 2010; Lango Allen et al., 2010; Speliotes
et al., 2010), bone mineral density (Estrada et al., 2012), risk of type 2
diabetes (Voight et al., 2010; Morris et al., 2012) and related traits
(fasting glucose, 2-h glucose, HbA1c, fasting insulin, proinsulin,
HOMA-IR, and HOMA-B) (Dupuis et al., 2010; Saxena et al., 2010;
Soranzo et al., 2010), and coronary artery disease (Coronary Artery
Disease Genetics C, 2011; Schunkert et al., 2011; Consortium CAD
and Deloukas, 2013) (Table S9, Supporting information). Many nominal
associations were expected because of the known influence of the IGF
system on these traits. Of note is the finding that for rs780093 in the
GCKR locus, the allele associated with higher IGF-I concentration was
already known to be associated with elevated risk of type 2 diabetes
(P = 3.7 9 106), as well as higher levels of fasting glucose, fasting
insulin, and HOMA-IR (all P < 2.0 9 104), lower 2-h glucose levels
(P = 1.7 9 106), increased height (P = 2.0 9 104), lower waist-to-
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Fig. 2 Overview of the NUBP2 locus that
shows the relations of gene expression
levels, protein levels and circulating IGF-I
and IGFBP-3 with respect to the SNP. Effect
directions () are given for the minor C-
allele of SNP rs1065656 (MAF 31%). Note:
the second signal rs11644716 (MAF 5%)
has opposite expression quantitative trait
loci (eQTL) and protein quantitative trait
analyses (pQTL) effect directions to
rs1065656, but they are consistent.
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hip ratio (P = 0.0003), and higher lumbar spine bone mineral density
(P = 0.002).
Three additional loci (GHSR, CELSR2, and FOXO3) showed strong
associations with height (all P < 1.0 9 104). The IGFBP-3-increasing
allele of SNP rs646776 (CELSR2 locus) was associated with increased risk
of coronary artery disease (P = 9.4 9 1015). The IGF-I-decreasing allele
of SNP rs934073 at ASXL2 showed a nominal association with survival
beyond 90 years (P = 0.018) as well as higher levels of BMI (P = 0.008)
and fat percentage (P = 9.4 9 105) and lower lumbar spine bone
mineral density (P = 0.004).
We further performed lookups of top IGF-I- and IGFBP-3-associated
SNPs (P < 106 in the meta-analysis of stage 1 and stage 2) for
associations with survival beyond 90 years using published GWAS data
(Broer et al., 2014) (Tables S10 and S11, Supporting information).
Among 15 independent circulating IGF-I-associated SNPs defined based
on linkage disequilibrium (LD) (settings r2 > 0.01, 1 Mb distance), the
SNP rs10457180 (r2 = 0.96 with the lead SNP rs2153960) at FOXO3
(P = 8.6 9 105) and SNP rs11892454 (r2 = 0.71 with the lead SNP
rs934073) at ASXL2 (P = 0.003) reached statistical significance after
Bonferroni correction for 15 independent tests. Among 13 indepen-
dent circulating IGFBP-3-associated SNPs, the SNP rs9398172 (r2 = 1
with the lead SNP rs2153960) at FOXO3 (P = 2.5 9 104) remained
significantly associated with survival beyond 90 years after Bonferroni
correction.
Enrichment of putative regulatory elements among loci
associated with circulating IGF-1 and IGFBP-3 concentrations
We examined whether the identified SNPs fall within regulatory
elements in the epigenetic ENCODE and ROADMAP data for associated SNPs
using Haploreg (http://www.broadinstitute.org/mammals/haploreg/hap-
loreg.php) (Ward & Kellis, 2012) and RegulomeDB (http://regu-
lomedb.org/) (Boyle et al., 2012) (Table S11, Supporting information).
Lower scores indicate stronger evidence for the presence of a regulatory
element. To determine whether these IGF-I- and IGFBP-3-associated loci
are enriched for regions likely to affect gene expression, we further
examined the distribution of scores among these SNPs compared with all
RegulomeDB SNPs. We found that these identified SNPs are highly
enriched for low Regulome scores (P < 2.2 9 1016 by multinomial
method, Fig. 3A). The genomic and representative epigenetic context
surrounding rs646776 (CELSR2 locus), a SNP with a Regulome score of
1f, is shown as an example (Fig. 3). SNP rs646776 localizes to a genomic
region of high LD (Fig. 3B) and lies within peaks of histone marks
associated with regulatory elements, and a DNase hypersensitivity region
(Fig. 3C)(Kent et al., 2002). In addition, SNP rs646776 falls in ChIP
identified binding regions for CTCF, POLR2A, REST, and TAF7 (data not
shown).
Discussion
Our second GWAS report from the CHARGE IGF Working Group, here
expanded to include more than >30 000 individuals, revealed several
SNPs influencing circulating levels of IGF-I and IGFBP-3 which also have
been associated with other metabolic and age-related traits. These
included several loci already implicated in the biology of GH/IGF-I (IGF1,
IGFBP3, IGFALS, GHSR, FOXO3) as well other novel findings including
rs934073 SNP on chr 2, which is an eQTL for polycomb group gene
ASXL2 associated with reduced circulating IGF-I. Cross-reference of IGF-
I- and IGFBP-3-associated SNPs against published GWAS of age-related
traits identified the ASXL2 SNP as a (to our knowledge) novel locus for
longevity as defined as survival beyond 90 years. All genomewide
significant associations with IGFBP-3 and IGF-I levels that were reported
in our preceding study (Kaplan et al., 2011) could be confirmed here
using a larger sample. Additionally, our preliminary finding of an
association of circulating IGF-I level with rs2153960 in the FOXO3 gene
reached genomewide significance using this larger sample size. More-
over, bioinformatics analysis also suggests enrichment of putative
regulatory elements among these IGF-I- and IGFBP-3-associated loci,
particularly of rs646776 at CELSR2.
Our study reveals clues about mechanisms of IGF system regulation
through the interplay of IGFBP-3 and genes within the NUBP2 locus,
including IGFALS and HAGH. The IGFALS encodes the insulin-like growth
factor-binding protein complex, acid labile subunit protein (ALS) which
forms a ternary complex with IGF-I and IGFBP-3 (Firth et al., 1998; Twigg
& Baxter, 1998). Like in most GWAS, our analyses cannot establish
which is the causative SNP or gene of a locus. However, IGFALS seems to
be a strong candidate supported by the associations of SNPs in the
vicinity of IGFALS with both circulating IGFBP-3 and plasma levels of the
protein coded by IGFALS. Although the sample size for the plasma
proteome analyses was restricted to 197 probands of SHIP-TREND, the
observed associations of the second signal rs11644716 achieved a
moderately high level of statistical significance (P < 0.0015). IGFALS was
not abundantly expressed in whole blood cells, and its transcript levels
were neither associated with IGF-I nor IGFBP-3 concentration. Certainly,
the protein ALS encoded by IGFALS is abundant in serum, but the gene is
translated in liver. In contrast to IGFALS, HAGH (hydroxyacylglutathione
hydrolase) was sufficiently expressed in whole blood cells and the
amount of its mRNA was strongly correlated with circulating IGFBP-3
serum concentration. Taking into account the eQTL association of the
lead SNP rs1065656 with HAGH and the correlation with the mRNA and
IGFBP-3, this SNP might influence the IGFBP-3 levels by modulating the
amount of HAGH mRNA, whereas both the levels of mRNA and IGFBP-3
are reduced per copy of the minor allele. Although this chain of
associations was revealed in whole blood, it might be present in other
tissues as well because significant eQTL for rs1065656 with HAGH were
observed in other tissues studied in the MuTHER dataset (Grundberg
et al., 2012). Given the more pronounced association with ALS and the
less significant eQTL with HAGH of the second signal compared with the
lead SNP, rs11644716 might reduce the level of circulating IGFBP-3
indirectly by reducing the amount of ALS per minor allele. Of note, there
was no nonsynonymous SNP in LD in the 1000 Genomes v3 dataset
(R² > 0.8, SHIP cohort) for both SNPs which could have helped narrow
down the functional mechanism.
Taken together with genotype–phenotype association data assem-
bled by others, our study revealed that IGF-I- and IGFBP-3-associated
SNPs had expected associations with anthropometric and age-related
chronic disease traits (e.g., bone mineral density, disordered carbohy-
drate metabolism). We also found that SNPs associated with reduced
IGF-I levels tended to be associated with longer survival defined as death
after 90 years (Broer et al., 2014). This is consistent with an observation
from prior analysis of candidate genes associated with the insulin and
IGF signaling axis (van Heemst et al., 2005). In addition, rs934073, an
eQTL for additional sex comb-like 2 (ASXL2), was a genomewide
significant SNP associated with lower IGF-I level which also has enriched
frequency in adults older than 90 years of age (Broer et al., 2014). Other
traits associated with the IGF-I-decreasing allele of rs934073 included
greater adiposity and reduced lumbar spine (but not femoral neck) bone
mineral density. ASXL2 is a polycomb group protein with known
functions in development that has also been associated with pediatric
cancer, but to our knowledge has not before been suggested as a
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longevity gene (Huether et al., 2014). The SNP in the known longevity
gene FOXO3 has not only been previously associated with reduced
fasting insulin and HOMA-IR (Willcox et al., 2008), but here it was found
to produce lower circulating IGF-I levels. Multiple genetic determinants
for circulating IGF-I in normal and IGF1R resistance states might partially
explain the U-shaped association of circulating IGF-I concentration with
mortality (Suh et al., 2008; Burgers et al., 2011).
While our meta-analysis encompasses a large number of samples
from multiple cohorts, this may lead to limitations. Given the different
origin of the cohorts (Table S1, Supporting information), heterogeneity
in the association results might occur due to the different genetic
background and the patterns of intake of nutrients across the individual
studies.
In summary, this project extends our prior work (Kaplan et al.,
2011) through the identification of several new loci related to
circulating IGF-I and IGFBP-3 levels that also may affect aging. While
the effects of insulin/IGF-I signaling on survival often displays sex
dimorphism in humans and other organisms, we found similar genetic
determinants of IGF protein levels in men and women, even with
relatively large sample size finding interaction by sex only for two loci
(IGFBP3 and SORCS2) in association with circulating IGFBP-3. Finally, a
novel identified gene candidate for long-term survival, ASXL2, requires
further study. Taking into account the design of our study, most of the
findings should be considered as important and well-grounded
hypotheses to work on.
Experimental procedures
Participating studies
In total, the CHARGE IGF Working Group included 21 and 13 studies
that participated in the association analysis for IGF-I (N = 27 520, 53%
women) and IGFBP-3 (N = 18 995, 58% women), respectively. Four of
the cohorts (N = 10 280) were previously included in a GWAS meta-
analysis of IGF-I and IGFBP-3 levels (Kaplan et al., 2011). Imputed SNPs
for chromosome X were available for 16 670 and 11 959 individuals
with IGF-I and IGFBP-3 measurements, respectively. Additionally, up to
3364 individuals (55% women) with IGF-I from one study were available
for de novo genotyping of selected SNPs. Detailed information on
participant characteristics, IGF-I and IGFBP-3 measurements, and geno-
typing of all studies participated in the different analyses and stages is
given in Table S2 (Supporting information). All participants provided
informed consent, and human subjects’ research review was obtained
from each participating cohort.
Statistical analyses
GWAS in individual studies
Each study of the GWAS stages performed genotyping on genomewide
arrays and imputed SNPs using the HapMap2 reference panel. Detailed
Fig. 3 Analysis of regulatory element marks in loci associated with serum IGF-1 and IGFBP-3 concentrations. (A) IGF-1- and IGFBP-3-associated SNPs are enriched for
putative regulatory elements compared with all SNPs in RegulomeDB. **P < 0.005, *P < 0.05 (Monte Carlo). Overall distribution of genomewide association study (GWAS)
SNPs vs. RegulomeDB SNPs P < 2.2E-16, multinomial method. (B) Genomic context surrounding rs646776 showing R2 values. (C) Representative regulatory motif tracks
from USCS Genome Browser and ENCODE showing histone mark peaks and DNase hypersensitivity at the location of rs646776.
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information on genotyping and imputation is provided in Table S2
(Supporting information). Association analyses in individual studies were
performed on IGF-I and IGFBP-3 levels measured in ng mL1 using a
multiple linear regression with an additive genetic model based on allele
dosages adjusted for age and stratified by sex. All cohorts accounted for
relatedness, population substructure using genetic principal compo-
nents, study center, and laboratory batch of IGF measurement where
applicable. Individuals of non-European ancestry, with missing pheno-
typic data, diagnosed growth hormone deficiency, or known use of
human growth hormones were excluded prior to the analyses.
Meta-analysis
From each cohort’s result file, monomorphic SNPs as well as SNPs with
an imputation quality below 0.3 were excluded prior to the meta-
analysis. All study-specific GWAS results were corrected by the genomic
inflation factor kGC if >1. Due to the IGF-I and IGFBP-3 assay-based
differences in both effect sizes and variances of measurements across
cohorts, a sample size-weighted z-score-based meta-analysis imple-
mented in METAL (Willer et al., 2010) was conducted, and the
meta-analysis P-values were corrected for genomic inflation. After
meta-analysis, SNPs with a MAF ≤1% were removed from subsequent
analyses.
Our multistage design had two GWAS stages (stages 1 and 2) and an
additional stage (stage 3) with de novo genotyping data (N = 3364
individuals) to confirm novel loci. After stage 1 GWAS, all 19 lead SNPs
from all traits with a P < 106 were taken forward to stage 2. All IGF-I
lead SNPs of novel loci that had a combined stage 1 and stage 2
P < 108 (except GCKR) were selected for de novo replication in an
additional cohort. An overview of the design and the significantly
associated loci at each stage is provided in Fig. S6 (Supporting
information). Details on SNP selection and quality control are given in
the Appendix S1 (Supporting information). Regional association plots
were generated using LocusZoom (Pruim et al., 2010).
Assessment of independent signals
To define a lead SNP of each locus, the association results of a GWAS
stage with P-values <1 9 105 were grouped based on the LD structure
of the HapMap release 28 CEU dataset using PLINK (settings r2 >0.01,
1 Mb distance) (Purcell et al., 2007). Due to the strong association of the
IGFBP3 locus with IGFBP-3, only one lead SNP was selected regardless of
several grouped results.
The analysis of secondary signals in the NUBP2 locus was performed
using the software GCTA (Yang et al., 2011) and the genotypes of the
SHIP cohort as a reference, and was verified by an analysis using the
genotypes of the NHS/HPFS cohorts as a reference.
Sex interaction analysis
Sex interactions on IGF-I and IGFBP-3 levels were obtained by comparing,
for each SNP, the stage 2 meta-analysis z-scores from men (z_men) (IGF-
I: N = 12 917, IGFBP-3: N = 8052) and women (z_women) (IGF-I:
N = 14 602, IGFBP-3: N = 10 942) using the formula z_interaction=
(z_men-z_women)/√2, assuming independent effect sizes between men
and women, and matched to a common effect allele.
Bivariate meta-analysis of IGF-I and IGFBP-3
The stage 2 meta-analysis z-scores of the combined samples IGF-I and
IGFBP-3 were used to calculate a bivariate meta-analysis implemented in
the function multipheno.T2 of the R-package gtx (version 0.0.8. http://
CRAN.R-project.org/package=gtx). The function corresponds closely
with Hotelling’s T2 test and calculates a multiphenotype association test
for each marker based on the meta-analysis result z-statistics that is
equivalent to using the subject-specific data to perform a multivariate
analysis of variance.
Gene-based analysis
Genomewide gene-based tests which account for both gene length and
LD between SNPs were performed by VEGAS 0.8.27 (Versatile Gene-Based
Association Study) (Liu et al., 2010) using SNP P-value results from the
overall meta-analyses. SNPs were allocated to one or more autosomal
genes using gene boundaries 50 kb. We performed 1 9 107 permu-
tations and defined a gene-based P-value <1 9 106 as gene-based
genomewide significant.
Gene expression and eQTL analysis
For each of the lead SNPs of the significant loci after final stage,
significant cis eQTL associations in whole blood, lymphocytes, subcuta-
neous fat, muscle, and skin were looked up in the publically available
association result databases (Grundberg et al., 2012; Westra et al.,
2013). Association analysis of whole blood gene expression data with
serum IGF-I and IGFBP-3 levels was conducted in 986 samples of the
SHIP-TREND cohort (Schurmann et al., 2012).
Association with plasma protein levels
Plasma proteome data were obtained as described in Appendix S1
(Supporting information) using liquid chromatography–mass spectrom-
etry (LC-MS). MASCOT (in-house MASCOT server v2.3.2; Matrix Science,
London, GB) search algorithm was used to match the generated peak
lists with a human FASTA-formatted database containing 20 268 unique
sequence entries (reviewed human database, release of October 2011).
Prior to data analyses, all peptide intensity values were log10-
transformed and median–median-normalized. Association analyses
between peptides and serum IGF-I and IGFBP-3 levels were performed
by linear regression, adjusted for age, sex, and the MS processing batch.
Associations of a SNP with the peptides were conducted by linear
regression, adjusted for age, sex, and the first four principal components
of a peptide-level-based principal component analysis. Protein intensities
used for analyses were obtained by averaging the corresponding peptide
intensities that passed the QC filter, and were put instead of the peptide
intensities into the association model. All measured peptides that passed
QC and that belonged to proteins which were encoded by genes located
in a 500-kb vicinity of our lead SNPs were selected for association
analyses. The assignment of protein names (uniprot identifiers) to the
corresponding genes was performed using the DAVID gene conversion
tool (http://david.abcc.ncifcrf.gov/). Finally, after QC the following
proteins measured in 197 SHIP-TREND samples were available: ALS,
CC121, IBP3, and RT34.
Lookups of top loci in association with IGF correlated traits
Top SNPs associated with levels of IGF-I and IGFBP-3 were examined in
relationship to other phenotypes using published data on serum
metabolites (Suhre et al., 2011; Shin et al., 2014), anthropometric
traits (Heid et al., 2010; Lango Allen et al., 2010; Speliotes et al.,
2010), bone mineral density (Estrada et al., 2012), diabetes (Voight
et al., 2010; Morris et al., 2012) and glycemic traits (Dupuis et al.,
2010; Saxena et al., 2010; Soranzo et al., 2010), coronary artery
disease (Coronary Artery Disease Genetics C, 2011; Schunkert et al.,
2011; Consortium CAD and Deloukas, 2013), and survival beyond
90 years (Broer et al., 2014). Detailed information of the published
datasets used including its references is given in Table S9 (Supporting
information).
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Assessment of regulatory elements associated with identified loci
ENCODE and ROADMAP data were assessed using HAPLOREG (http://
www.broadinstitute.org/mammals/haploreg/haploreg.php) and REGU-
LOMEDB (http://regulomedb.org/). Statistical analysis of individual Regu-
lome scores was performed using Monte Carlo sampling of 10 SNPs (the
size of our ‘observed data’ pool). RegulomeDB assigns scores to SNP loci
based on the presence of histone marks, predicted and experimentally
validated transcription factor binding, DNase hypersensitivity, and other
evidence for regulatory function. Scores range from 1 to 7, with lower
scores indicating stronger evidence for the presence of a regulatory
element. For the purpose of this analysis, score subcategories (1a, 1b,
etc.) were merged. A multinomial test was performed for a statistical
comparison between the observed distribution and the background
distribution. The LD plot in Fig. 3B was generated using HAPLOVIEW 4.2
with genetic data downloaded from version 3, Release 2, using the
genomic region Chr1:109590000-109630000, and analysis panel
CEU + TSI. Histone mark and DNase tracks in Fig. 3C were downloaded
from UCSC Genome Browser.
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